azathioprine rheum
Selected indexed studies
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. (Ann Rheum Dis, 2024) [PMID:37827694]
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. (Ann Rheum Dis, 2024) [PMID:36927642]
- Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. (Ann Rheum Dis, 2023) [PMID:36958796]
_Worker-drafted node — pending editorial review._
Connections
azathioprine rheum is a side effect of
Sources
- Azathioprine. (1984) pubmed
- EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. (2020) pubmed
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. (2024) pubmed
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. (2024) pubmed
- Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. (2023) pubmed
- Update οn the diagnosis and management of systemic lupus erythematosus. (2021) pubmed
- EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. (2025) pubmed
- 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. (2019) pubmed
- Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. (2002) pubmed
- 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. (2020) pubmed